The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Combination of plasma microRNAs with serum CA19‐9 for early detection of pancreatic cancer
Abstract
This study was performed to identify plasma microRNAs (miRNAs) as diagnostic biomarkers for pancreatic cancer (PCa) and to assess their supplementary role with serum CA19‐9 in early identification of tumors. Plasma RNAs were extracted from 140 PCa patients, 111 chronic pancreatitis (CP) patients and 68 normal controls, and the relative abundances of seven miRNAs (miR‐16, 21, 155, 181a, 181b, 196a and 210) were measured using real‐time PCR. Their diagnostic utility for PCa and correlation with clinical characteristics were analyzed. All seven miRNAs were significantly aberrantly upregulated in the PCa group compared with both the CP and normal groups, between which only four miRNAs (miR‐155, 181a, 181b and 196a) were significantly different. Logistic modeling proved that only miR‐16 and miR‐196a possessed an independent role in discriminating PCa from normal and CP. Furthermore, after including serum CA19‐9 in the logistic model, the combination of miR‐16, miR‐196a and CA19‐9 was more effective for discriminating PCa from non‐PCa (normal+CP) (AUC‐ROC, 0.979; sensitivity, 92.0%; specificity, 95.6%), and for discriminating PCa from CP (AUC‐ROC, 0.956; sensitivity, 88.4%; specificity, 96.3%) compared with the miRNA panel (miR‐16+miR‐196a) or CA19‐9 alone. Most significantly, the combination was effective at identification of tumors in Stage 1 (85.2%). In conclusion, plasma miRNAs were effective for distinguishing PCa from non‐PCa (normal+CP). The combination of miR‐16, miR‐196a and CA19‐9 was more effective for PCa diagnosis, especially in early tumor screening.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer
Taylor, D. D., & Gercel-Taylor, C. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.033 · Cited by 2,288
RetractedBartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
Circulating microRNAs as stable blood-based markers for cancer detection
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804549105 · Cited by 7,969
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242606799 · Cited by 5,111
Resected adenocarcinoma of the pancreas—616 patients: results, outcomes, and prognostic indicators
Sohn, T. A., Yeo, C. J., Cameron, J. L., Koniaris, L., Kaushal, S., Abrams, R. A., Sauter, P. K., Coleman, J., Hruban, R. H., & Lillemoe, K. D. (2000) · Journal of Gastrointestinal Surgery · doi:10.1016/s1091-255x(00)80105-5 · Cited by 1,485
Detection of microRNA Expression in Human Peripheral Blood Microvesicles
Hunter, M. P., Ismail, N., Zhang, X., Aguda, B. D., Lee, E. J., Yu, L., Xiao, T., Schafer, J., Lee, M.-L. T., Schmittgen, T. D., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003694 · Cited by 1,452
Wang, G.-K., Zhu, J.-Q., Zhang, J.-T., Li, Q., Li, Y., He, J., Qin, Y.-W., & Jing, Q. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq013 · Cited by 1,170
Bloomston, M., Frankel, W. L., Petrocca, F., Volinia, S., Alder, H., Hagan, J. P., Liu, C.-G., Bhatt, D., Taccioli, C., & Croce, C. M. (2007) · JAMA · doi:10.1001/jama.297.17.1901 · Cited by 1,141
Cited by
Clinical relevance of circulating cell-free microRNAs in cancer
Schwarzenbach, H., Nishida, N., Calin, G. A., & Pantel, K. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.5 · Cited by 969
Madhavan, B., Yue, S., Galli, U., Rana, S., Gross, W., Müller, M., Giese, N. A., Kalthoff, H., Becker, T., Büchler, M. W., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29324 · Cited by 495
Data Normalization Strategies for MicroRNA Quantification
Schwarzenbach, H., da Silva, A. M., Calin, G., & Pantel, K. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2015.239459 · Cited by 468
MicroRNA Biomarkers in Whole Blood for Detection of Pancreatic Cancer
Schultz, N. A., Dehlendorff, C., Jensen, B. V., Bjerregaard, J. K., Nielsen, K. R., Bojesen, S. E., Calatayud, D., Nielsen, S. E., Yilmaz, M., Holländer, N. H., et al. (2014) · JAMA · doi:10.1001/jama.2013.284664 · Cited by 450
Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter
Luo, G., Jin, K., Deng, S., Cheng, H., Fan, Z., Gong, Y., Qian, Y., Huang, Q., Ni, Q., Liu, C., et al. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188409 · Cited by 446
Self-citationEarly screening and diagnosis strategies of pancreatic cancer: a comprehensive review
Yang, J., Xu, R., Wang, C., Qiu, J., Ren, B., & You, L. (2021) · Cancer Communications · doi:10.1002/cac2.12204 · Cited by 379
CA 19-9: Biochemical and Clinical Aspects
Scarà, S., Bottoni, P., & Scatena, R. (2015) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-017-7215-0_15 · Cited by 351
Pancreatic Cancer: A Review of Risk Factors, Diagnosis, and Treatment
Zhao, Z., & Liu, W. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820962117 · Cited by 348
MicroRNAs as Potential Biomarkers in Cancer: Opportunities and Challenges
Lan, H., Lu, H., Wang, X., & Jin, H. (2015) · BioMed Research International · doi:10.1155/2015/125094 · Cited by 330
Self-citationTong, Y.-S., Wang, X.-W., Zhou, X.-L., Liu, Z.-H., Yang, T.-X., Shi, W.-H., Xie, H.-W., Lv, J., Wu, Q.-Q., & Cao, X.-F. (2015) · Molecular Cancer · doi:10.1186/1476-4598-14-3 · Cited by 317
Self-citationLi, A., Yu, J., Kim, H., Wolfgang, C. L., Canto, M. I., Hruban, R. H., & Goggins, M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3092 · Cited by 293
Rationally Engineered Nucleic Acid Architectures for Biosensing Applications
Xiao, M., Lai, W., Man, T., Chang, B., Li, L., Chandrasekaran, A. R., & Pei, H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00121 · Cited by 290
Pancreatic Cancer in Chronic Pancreatitis
Dhar, P., Kalghatgi, S., & Saraf, V. (2015) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-014-0373-9 · Cited by 261
The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer
Johansen, J. S., Calatayud, D., Albieri, V., Schultz, N. A., Dehlendorff, C., Werner, J., Jensen, B. V., Pfeiffer, P., Bojesen, S. E., Giese, N., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30291 · Cited by 47
Metadata
- Authors
- Liu, J., Gao, J., Du, Y., Li, Z., Ren, Y., Gu, J., Wang, X., Gong, Y., Wang, W., & Kong, X.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2011-11-19
- Volume
- 131
- Issue
- 3
- Pages
- 683-691
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1981337389
- Cited by
- 309
- References
- 46
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.